Weight-Loss Drug Prescriptions for Kids Ages 8 to 11 Jumped 310-Fold, but the Study Reveals a Surprising Reality About Who Gets Them

Prescriptions for GLP-1 weight-loss medications among children ages 8 to 11 have increased dramatically, according to the research highlighted in the New York Post’s September 4 report. Researchers found that prescribing rates rose 310-fold between 2019 and June 2026, bringing renewed attention to the use of these medications in younger patients. However, the findings come with an important qualification because the study examined children with obesity who did not have diabetes, rather than all American children under 12.

Across the 7.5-year study period, 20,282 children in the eight-to-11 age group received prescriptions for GLP-1 receptor agonists. Yet only 0.6% of the more than 3.5 million children included in the research received a prescription during that period. The contrast between the enormous percentage increase and the relatively small overall share is central to understanding what the findings actually mean.

Prescriptions Increased 310-Fold From a Very Small Starting Point

The research, published in the medical journal Pediatrics, examined prescribing patterns among children with obesity who did not have diabetes. The proportion receiving GLP-1 prescriptions rose from 0.03% in 2019 to 9.3% in June 2026, according to the original research paper. That change represents a 310-fold increase, demonstrating how quickly prescribing practices shifted within the population being studied.

The starting percentage was extremely small, which helps explain why the relative increase looks so dramatic. A 310-fold rise does not mean that prescriptions increased by 310 percentage points or that 310 times as many children across the entire country are taking medication. The researchers also reported that just 0.6% of the complete study population received a prescription at some point during the observation period, a figure that provides important perspective on the headline number.

Researchers Analyzed Millions of Children’s Health Records

The study examined records for 3,520,531 children ages 8 to 11 who had obesity but no diabetes, as Reuters reported in its coverage. Researchers used Epic Cosmos, a large electronic health-record database containing information from more than 300 million patients in the United States. Their analysis covered the period from January 1, 2019, through June 17, 2026.

The size of the dataset allowed researchers to examine prescribing trends across several years and compare patterns among different groups of children. Nevertheless, the research was a retrospective analysis of electronic health records rather than a randomized clinical trial. It was designed to measure prescribing patterns, not to establish whether each child benefited from medication or why a particular doctor chose to prescribe it.

The Findings Apply to a Specific Group of Children

The study focused specifically on children who had obesity and did not have diabetes, so its findings should not be interpreted as a measure of weight-loss drug use among every child under 12. According to the Centers for Disease Control and Prevention, childhood obesity is generally defined using body mass index, or BMI, at or above the 95th percentile for children of the same age and sex. This approach accounts for differences in normal growth and development as children get older.

The distinction is important because the 9.3% figure refers to the prescribing measure for the relevant group in 2026, not to all American children younger than 12. The study also excluded children with diabetes, meaning its findings do not describe every possible medical reason a child might receive a GLP-1 medication. Consequently, the results provide a focused view of obesity treatment in younger patients rather than a complete picture of pediatric medication use across the country.

Most Prescribed Children Had Severe Obesity

One of the study’s most important findings was the extent of obesity among children who received prescriptions. Approximately 93.7% of the children prescribed GLP-1 medications had severe obesity, according to the research team at NYU Langone Health. This suggests that prescriptions were concentrated among children facing particularly serious weight-related health concerns rather than being distributed evenly across the study population.

Severe obesity in children is assessed relative to age and sex, reflecting the fact that a child’s healthy growth pattern differs from that of an adult. The findings suggest that doctors were more likely to prescribe these medications for children with greater medical needs. However, the records cannot establish the reasoning behind every individual prescribing decision or whether every prescription was appropriate for a particular patient.

Related Health Conditions Were Common Among Young Patients

Obesity was not the only health concern identified among the children who received GLP-1 prescriptions. Approximately 65.2% had at least one obesity-related health condition, with examples including high cholesterol, high blood pressure and sleep apnea. These findings help explain why doctors may consider medical treatment for some younger children rather than relying on weight measurements alone.

The study also found that approximately one-quarter of the children receiving prescriptions had prediabetes, a condition associated with an increased risk of developing type 2 diabetes. These accompanying health concerns place the rise in prescriptions within a broader clinical context. However, the study did not measure whether the medications improved these conditions in the children included in its analysis.

Older Children Were More Likely to Receive Prescriptions

Age made a measurable difference in prescribing patterns within the eight-to-11 age group. The study reported approximately 79.5 prescriptions per 10,000 children among 11-year-olds, compared with 41.5 per 10,000 among eight-year-olds. In other words, prescribing was considerably more common among children at the older end of the age range.

That difference does not establish why physicians made different decisions for younger and older children. Medical needs, the severity of obesity and the presence of related health conditions may all be relevant to treatment decisions, but the observed age pattern alone cannot identify the cause. The findings instead show that GLP-1 prescribing was not spread evenly across all ages in the study population.

Girls Were More Likely Than Boys to Receive the Drugs

The researchers also found a difference between girls and boys. The prescribing rate was approximately 75.9 per 10,000 girls, compared with 42.8 per 10,000 boys. This indicates that girls in the study population were more likely to receive a prescription for one of the medications.

The research did not establish why this difference occurred. It would therefore be premature to attribute the pattern to a particular biological, social or behavioral explanation without additional evidence. The finding identifies a difference worth examining in future research, particularly as physicians continue to evaluate treatment options for children with obesity.

Income and Access to Care Also Shaped the Picture

The researchers identified another notable pattern involving the communities where children lived. Children from higher-income communities were reported to be 55% more likely to receive GLP-1 prescriptions than children in the most socially vulnerable communities. The finding raises questions about whether access to treatment is keeping pace with the growing use of these medications.

In reporting the results, the NYU Langone Health research team highlighted concerns about the potential divide between families who can obtain treatment and those who face financial or healthcare-access barriers. The study demonstrates an association between social circumstances and prescribing, but it does not prove exactly why the difference exists. Insurance coverage, treatment costs and access to pediatric specialists are relevant considerations, although the analysis does not establish how much each factor contributed to the observed gap.

The Medications Work Through a Specific Hormonal Pathway

The drugs examined in the study included Saxenda, Wegovy and Zepbound, medications associated with glucagon-like peptide-1, or GLP-1, treatment. GLP-1 receptor agonists act on pathways involved in appetite and blood sugar regulation, and they can help patients lose weight when used for appropriate medical indications. Their inclusion in the study reflects the growing role of these medicines in treating obesity.

Although these medications belong to a related treatment category, their approved uses and prescribing requirements are not identical. The research measured prescriptions for the specified drugs rather than comparing their effectiveness against one another. It therefore does not establish which medication works best for children ages 8 to 11 or whether one option offers greater benefits or fewer risks for this age group.

Prescribing Children Under 12 Remains Outside the Approved Obesity Indication

The sharp increase has attracted attention partly because these drugs do not have an FDA-approved indication specifically for treating obesity in children younger than 12. For example, the Food and Drug Administration’s approval of Saxenda for pediatric weight management established eligibility beginning at age 12, subject to the specified medical criteria. Prescribing a medication for an age group or indication outside its approved labeling is generally described as off-label use.

Off-label prescribing is distinct from a drug receiving formal regulatory approval for the population being treated. It can occur in medical practice, but it requires clinical judgment about a medication’s potential benefits, risks and available evidence. The study documents how often these prescriptions appeared in health records; it does not independently establish that every prescription was appropriate or that all children in this age group should receive these drugs.

Pediatric Guidelines Allow Medication in Selected Cases

The lack of an approved obesity indication for children under 12 does not mean that pediatric medical guidance rules out all medication treatment for younger children. The American Academy of Pediatrics’ 2023 clinical practice guideline states that clinicians may offer weight-loss pharmacotherapy to children ages 8 through 11 according to the medication’s indications, risks and benefits. The guideline describes medication as an addition to health behavior and lifestyle treatment rather than a replacement for it.

The guidance also makes an important distinction about the available evidence for children younger than 12. It found insufficient evidence to recommend pharmacotherapy solely for obesity across this younger age group, while recognizing that particular medical circumstances may justify additional treatment options. Decisions therefore require individualized assessment instead of treating the age range as a single group with identical needs.

The Study Does Not Settle Questions About Long-Term Safety

A major limitation of the research is that it tracks prescribing patterns rather than long-term health outcomes. Because the analysis was observational and retrospective, it cannot establish whether the medications caused specific improvements or complications in the children who received prescriptions. It also cannot settle questions about the long-term effects of GLP-1 treatment while children are still growing and developing.

Those questions matter because prescribing trends can change faster than the evidence needed to guide treatment over many years. Researchers need further data to assess how the medications perform in younger children, which patients benefit most and what risks might emerge with prolonged use. The sharp rise in prescriptions therefore identifies an important area for continued investigation rather than providing a final answer about the safest approach to childhood obesity.

Future Research Could Change How Younger Children Are Treated

The NYU Langone research team has noted that clinical trials involving children as young as 6 are underway, with the aim of providing additional evidence about obesity treatments in younger age groups. Such research could help clinicians, policymakers and families better understand the benefits and risks of medication before deciding how broadly these treatments should be used. Until more results are available, long-term monitoring remains an important part of evaluating the medications in children.

For now, the central finding is clear: GLP-1 prescriptions for children ages 8 to 11 with obesity increased dramatically between 2019 and 2026, even though the overall proportion of the study population receiving prescriptions remained relatively small. Most prescribed children had severe obesity, many had additional health conditions, and access appeared to differ according to socioeconomic circumstances. The next challenge will be determining how to balance the potential benefits of treatment with the need for stronger evidence, careful medical oversight and fair access for children who may need it.